Silver Book Fact

One economic model predicts that if type 1 and type 2 diabetics had begun Captopril (a drug that controls blood pressure and delays the onset of kidney failure) treatment in 1995, the aggregate health care cost savings in 1999 would have been $189 million and in 2004 would have been $475 million-a present value cumulative cost savings of $2.4 billion for those 10 years.

Rodby, Roger A., Louise Firth, and Edmund J. Lewis. An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy. Diabetes Care. 1996; 19(10): 1051-61. http://care.diabetesjournals.org/cgi/content/abstract/19/10/1051

Reference

Title
An Economic Analysis of Captopril in the Treatment of Diabetic Nephropathy
Publication
Diabetes Care
Publication Date
1996
Authors
Rodby, Roger A., Louise Firth, and Edmund J. Lewis
Volume & Issue
Volume 19, Issue 10
Pages
1051-61
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • For every 10 mmHg reduction in systolic blood pressure, the risk of diabetic complications is reduced by 12%.  
  • The use of insulin pumps create net cost savings, including $5886 annually per person affected and $34.9 million in increased tax revenue  
  • A statin initiation intervention aimed at Medicare Part D prescription drug plan subscribers with diabetes or coronary artery disease was successful in increasing statin use among this group of members…  
  • To date, multiple genomewide comparisons of thousands of subjects with type 2 diabetes and controls without the disease have identified approximately twenty-five DNA variants that are significantly associated with type…  
  • Detecting and treating diabetic eye disease with laser therapy can reduce the development of severe vision loss by an estimated 50% to 60%.